Restructuring Costs

3 Months Ended

Mar. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring Costs

10. Restructuring Costs

In June 2016, the Company halted investment in PNT2258 and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the three months ended March 31, 2018:

	Contract Termination
	(in thousands)
Accrual balance at December 31, 2017	$	137
Cash payments		(38	)
Accrual balance at March 31, 2018	$	99

The accrual balance is currently expected to be substantially paid by the end of 2018.